ESR1 and breast cancer: A phase III trial of oral SERDs has demonstrated efficacy in modulating ER-regulated gene expression and antiproliferation in ESR1 wild-type and mutant cells, demonstrating efficacy in treating early and advanced ER+ breast cancer.